CAMP4 Therapeutics Corp. (CAMP), a clinical-stage biotechnology company that went public in 2024, anticipates 2025 to be a crucial year, with a key clinical trial catalyst expected in the second half of the year.
The company is pioneering a new class of RNA medicines to increase targeted gene expression, with the potential to provide meaningful clinical benefits for prevalent diseases where gene upregulation is likely to be effective. Its lead drug candidate is CMP-CPS-001, being developed for the treatment of Urea Cycle Disorders.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.